TechNavio's analysts forecast the Global Next-generation Cancer Diagnostic Devices market to grow at a CAGR of 48.11 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of cancer. The Global Next-generation Cancer Diagnostic Devices market has also been witnessing an increase in mergers and acquisitions among vendors. However, intense competition among vendors could pose a challenge to the growth of this market.... Research Beam Model: Research Beam Product ID: 16388 2000 USD New
Global Next Generation Cancer Diagnostic Devices Market 2012-2016
 
 

Global Next Generation Cancer Diagnostic Devices Market 2012-2016

  • Category : Healthcare
  • Published On : March   2013
  • Pages : 35
  • Publisher : Technavio
 
 
 

TechNavio's analysts forecast the Global Next-generation Cancer Diagnostic Devices market to grow at a CAGR of 48.11 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of cancer. The Global Next-generation Cancer Diagnostic Devices market has also been witnessing an increase in mergers and acquisitions among vendors. However, intense competition among vendors could pose a challenge to the growth of this market. 



TechNavio's report, Global Next-generation Cancer Diagnostic Devices Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Next-generation Cancer Diagnostic Devices market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.



The key vendors dominating this space are Roche Holding Ltd., Abbott Laboratories, Siemens Healthcare, and Agilent Technologies Inc.



The other vendors mentioned in the report are Illumina Inc., Becton Dickinson and Co., QIAGEN N.V., Affymetrix Inc., Johnson & Johnson, Thermo Fisher Scientific Inc., GE Healthcare, Life Technologies Corp., Luminex Corp., Cepheid Inc., bioMerieux SA, Allegro Diagnostics Corp., Fluidigm Corp., Nanosphere Inc., PerkinElmer Inc., Randox Laboratories Ltd., Oncolys BioPharma Inc., SomaLogic Inc., Radient Pharmaceuticals Corp., Quest Diagnostics Inc., Asuragen Inc., AVIVA Biosciences Corp., Veridex LLC, A. Menarini Diagnostics S.r.l., and Fujirebio Diagnostics Inc.



Key questions answered in this report:

What will the market size be in 2016 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of each of these key vendors?


01. Executive Summary

02. Introduction

03. Market Coverage


Market Overview

Product Offerings

04. Market Landscape

04.1 Market Size and Forecast

04.2 Market Segmentation

04.3 Five Forces Analysis

05. Geographical Segmentation

06. Vendor Landscape


Major Vendors in the Global In Vitro Diagnostics Market 

07. Buying Criteria

08. Market Growth Drivers

09. Drivers and their Impact

10. Market Challenges

11. Impact of Drivers and Challenges

12. Market Trends

13. Key Vendor Analysis


13.1 Roche Holding Ltd.

Business Overview

Key Information

SWOT Analysis

13.2 Abbott Laboratories

Business Overview

Key Information

SWOT Analysis

13.3 Agilent Technologies Inc.

Business Overview

Key Information

SWOT Analysis

13.4 Siemens Healthcare

Business Overview

Key Information

SWOT Analysis

14. Other Reports in this Series



List of Exhibits

Exhibit 1: Global Next-generation Cancer Diagnostic Devices Market 2012-2016 (US$ billion)

Exhibit 2: Global Next-generation Cancer Diagnostic Devices Market Segmentation 

Exhibit 3: Global Next-generation Cancer Diagnostic Devices Market Segmentation 2012

Exhibit 4: Global Next-generation Cancer Diagnostic Devices Market by Geographical Segmentation 2012

Exhibit 5: Global In Vitro Diagnostics Market by Vendor Segmentation 2012

Exhibit 6: Business Segmentation of Roche Holding Ltd.

Exhibit 7: Business Segmentation of Abbott Laboratories

Exhibit 8: Business Segmentation of Agilent Technologies Inc.



 



PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 

Related Reports

REQUEST SAMPLE    ASK FOR DISCOUNT